Clinical trials in Boulogne sur Mer

39 clinical trials in Boulogne sur Mer, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Boulogne sur Mer at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

39 trials in Boulogne sur Mer

Open in trial search

Colorectal cancer stage III

Recruiting

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fruquintinib
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Renal cell carcinoma

Recruiting

Study on Digital Monitoring of Symptoms in Patients with Advanced Kidney Cancer Treated with Cabozantinib and Nivolumab

Registered drugNo placebo

Study on Digital Monitoring of Symptoms in Patients with Advanced Kidney Cancer Treated with Cabozantinib and Nivolumab

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Centre Francois Baclesse

Contact Research Centre

Breast cancer metastatic

Recruiting

Study on Detecting Tumor DNA in Blood for Patients with HR+, HER2 Low Metastatic Breast Cancer Using Trastuzumab Deruxtecan After Standard Therapy

InvestigationalNo placebo

Study on Detecting Tumor DNA in Blood for Patients with HR+, HER2 Low Metastatic Breast Cancer Using Trastuzumab Deruxtecan After Standard Therapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Unicancer

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX

Registered drugNo placebo

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Colon cancer

Recruiting

Study on Using Oxaliplatin, Fluorouracil, and Folinic Acid for Treating Stage II Colon Cancer in Patients with Positive Circulating Tumor DNA

Registered drugNo placebo

Study on Using Oxaliplatin, Fluorouracil, and Folinic Acid for Treating Stage II Colon Cancer in Patients with Positive Circulating Tumor DNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Atrial fibrillation+1

Recruiting

Study on the Safety and Effectiveness of Apixaban and Warfarin for Patients with End-Stage Renal Disease on Peritoneal Dialysis and Atrial Fibrillation

Registered drugNo placebo

Study on the Safety and Effectiveness of Apixaban and Warfarin for Patients with End-Stage Renal Disease on Peritoneal Dialysis and Atrial Fibrillation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Contact Research Centre

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Colon cancer

Recruiting

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Boulogne sur Mer

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials exploring treatments for various cancers, with focus on pancreatic adenocarcinoma, breast cancer, and colorectal cancer. Studies evaluate novel therapeutic approaches including targeted therapies and immunotherapy combinations.

Metastatic Cancer Treatment
Circulating Tumor DNA Analysis
Adjuvant Therapy Optimization

Advanced research includes evaluation of treatment efficacy in hormone receptor-positive breast cancer and hepatocellular carcinoma.

02 Cardiovascular and Renal Studies

Innovative trials investigating treatments for chronic kidney disease and cardiovascular conditions. Research focuses on blood thinners, dialysis patients, and prevention of stroke in high-risk populations.

Stroke Prevention
Renal Disease Management
Cardiovascular Risk Reduction

Studies examine novel approaches to treating end-stage renal disease and improving cardiovascular outcomes.

03 Autoimmune Conditions

Clinical trials examining treatments for various autoimmune disorders, including ANCA-associated vasculitis, IgA nephropathy, and rheumatoid arthritis. Research evaluates new therapeutic agents and treatment strategies.

Vasculitis Treatment
Immunotherapy Approaches
Disease Remission Studies

Investigations include comparative studies of biological agents and optimization of immunosuppressive therapies.

Back to France All countries